カポジ肉腫の世界市場

カポジ肉腫の世界市場は2030年までに2億140万米ドルに達する見込み

2024年に1億6,700万米ドルと推定されるカポジ肉腫の世界市場は、2024～2030年の分析期間においてCAGR 3.2%で成長し、2030年には2億140万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるHAARTは、CAGR 3.2%を記録し、分析期間終了時には1億150万米ドルに達すると予測されます。化学療法セグメントの成長率は、分析期間中CAGR 2.5％と推定されます。

米国市場は4,530万米ドルと推定、中国はCAGR 3.1％で成長予測

米国のカポジ肉腫市場は2024年に4,530万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを3.1%として、2030年までに3,220万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9％と2.6％と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界のカポジ肉腫市場- 主要動向と治療イノベーション

カポジ肉腫ががん領域で重要な関心事である理由とは？

カポジ肉腫（KS）は、リンパ管や血管を取り囲む細胞から発症するまれながんであり、免疫不全の患者、特にHIV/AIDS患者に最もよく見られます。皮膚に病変が現れるが、内臓を侵すこともあり、その攻撃的な性質と引き起こす合併症のため、腫瘍学において重要な関心事となっています。かつてKSは比較的まれな疾患と考えられていたが、HIV/AIDSの流行により、特に抗レトロウイルス療法（ART）へのアクセスが限られている地域では、その有病率が劇的に増加しました。HIV治療の進歩にもかかわらず、カポジ肉腫は、特にサハラ以南のアフリカでは、HIV感染率が高く、ヘルスケアへのアクセスが限られているため、最も一般的ながんの1つであり、依然として重要な問題です。

カポジ肉腫の治療アプローチはどのように進化しているのか？

カポジ肉腫の治療アプローチは、腫瘍学とHIV/AIDS治療の進歩によって進化しています。KSの主な治療には抗レトロウイルス療法（ART）があり、HIV感染を抑制し、結果としてKS病変の退縮につながります。しかし、KSがより侵攻性であったり、ARTに十分に反応しない場合には、化学療法、放射線療法、標的治療などの追加治療が行われます。最近の標的療法と免疫療法の動向は、難治性KS患者に新たな希望をもたらしています。KSに関与する分子経路を特異的に標的とする治療薬が臨床試験で有望視されており、より効果的で毒性の少ない治療が可能になる可能性があります。さらに、KSに強く関連するヒトヘルペスウイルス8（HHV-8）の役割の解明が進み、このがんをより効果的に予防または治療することを目的とした新規治療戦略への道が開かれつつあります。

カポジ肉腫の治療と管理にはどのような課題があるか？

カポジ肉腫の治療と管理には、特に資源が限られた環境ではいくつかの課題があります。主な課題の一つは、特にヘルスケアのインフラが未発達な地域における、KSの早期発見と診断です。KSの多くの症例は診断されなかったり、治療が困難な末期に診断されたりします。さらに、HIV/AIDSにまつわるスティグマ（烙印）が、患者が適時に医療を受けることを妨げ、KSの管理をさらに複雑にしています。治療へのアクセスも重要な課題であり、低所得地域の患者の多くは、ARTや必要な腫瘍学的治療を受けることができないです。さらに、医療インフラが整っている地域でも、現在の治療法では有効性や忍容性に限界があるため、副作用の少ないより効果的な治療法が求められています。このような課題に対処するには、ARTへのアクセス改善、診断能力の向上、より効果的で利用しやすい治療法の開発など、多面的なアプローチが必要です。

カポジ肉腫市場における調査と治療の進歩を促進する要因とは？

カポジ肉腫治療市場の成長は、HIV/AIDSの流行の進行、がん研究の進歩、標的治療の市場開拓など、いくつかの要因によってもたらされています。特にサハラ以南のアフリカなどの地域ではHIVの流行が続いており、KSに対する効果的な治療法の必要性が強調されています。ARTプログラムの世界の拡大は、KSの罹患率と治療成績に大きな影響を与え、HIVとがんの統合治療に対する需要を促進しています。さらに、がん研究の進歩、特にKSの根底にある分子およびウイルスメカニズムの解明は、より的を絞った効果的な治療法の開発につながっています。免疫療法や標的治療への関心の高まりも、治療抵抗性のKS患者に新たな希望をもたらすものとして、市場の成長に寄与しています。研究が継続され、先進治療へのアクセスが改善されるにつれて、KS治療市場は拡大し、世界中の患者により良い結果をもたらすことが期待されます。

セグメント

治療タイプ（HAART、化学療法、免疫療法）

調査対象企業の例（注目の14社）

• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Kaposi Sarcoma Market to Reach US$201.4 Million by 2030

The global market for Kaposi Sarcoma estimated at US$167.0 Million in the year 2024, is expected to reach US$201.4 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$45.3 Million While China is Forecast to Grow at 3.1% CAGR

The Kaposi Sarcoma market in the U.S. is estimated at US$45.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.2 Million by the year 2030 trailing a CAGR of 3.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Kaposi Sarcoma Market - Key Trends & Treatment Innovations

Why Is Kaposi Sarcoma a Significant Concern in Oncology?

Kaposi Sarcoma (KS) is a rare form of cancer that develops from the cells that line lymph or blood vessels and is most commonly associated with immunocompromised individuals, particularly those with HIV/AIDS. It manifests as lesions on the skin, but it can also affect internal organs, making it a significant concern in oncology due to its aggressive nature and the complications it can cause. While KS was once considered relatively rare, the rise of the HIV/AIDS epidemic dramatically increased its prevalence, particularly in regions with limited access to antiretroviral therapy (ART). Despite advancements in HIV treatment, Kaposi Sarcoma remains a critical issue, especially in sub-Saharan Africa, where it is one of the most common cancers due to the high rates of HIV infection and limited access to healthcare.

How Are Treatment Approaches for Kaposi Sarcoma Evolving?

Treatment approaches for Kaposi Sarcoma are evolving, driven by advancements in both oncology and HIV/AIDS treatment. The primary treatment for KS involves antiretroviral therapy (ART), which helps control HIV infection and, consequently, can lead to the regression of KS lesions. However, in cases where KS is more aggressive or does not respond adequately to ART, additional treatments such as chemotherapy, radiation therapy, and targeted therapies are employed. Recent developments in targeted therapy and immunotherapy are offering new hope for patients with refractory KS. Drugs that specifically target the molecular pathways involved in KS are showing promise in clinical trials, offering the potential for more effective and less toxic treatments. Moreover, advancements in understanding the role of the human herpesvirus 8 (HHV-8), which is strongly associated with KS, are paving the way for novel therapeutic strategies aimed at preventing or treating this cancer more effectively.

What Challenges Exist in the Treatment and Management of Kaposi Sarcoma?

The treatment and management of Kaposi Sarcoma present several challenges, particularly in resource-limited settings. One of the primary challenges is the early detection and diagnosis of KS, especially in regions where healthcare infrastructure is underdeveloped. Many cases of KS go undiagnosed or are diagnosed at a late stage, when the disease is more difficult to treat. Additionally, the stigma associated with HIV/AIDS can prevent individuals from seeking timely medical care, further complicating the management of KS. Access to treatment is another significant challenge, as many patients in low-income regions do not have access to ART or the necessary oncology care. Furthermore, even in regions with better healthcare infrastructure, there is still a need for more effective therapies with fewer side effects, as current treatment options can be limited in their efficacy and tolerability. Addressing these challenges requires a multifaceted approach, including improving access to ART, enhancing diagnostic capabilities, and developing more effective and accessible treatments.

What Factors Are Driving Research and Treatment Advancements in the Kaposi Sarcoma Market?

The growth in the Kaposi Sarcoma treatment market is driven by several factors, including the ongoing HIV/AIDS epidemic, advancements in cancer research, and the development of targeted therapies. The continuing prevalence of HIV, particularly in regions like sub-Saharan Africa, underscores the need for effective treatments for KS. The expansion of ART programs globally has significantly impacted KS incidence and treatment outcomes, driving demand for integrated HIV and cancer care. Additionally, the progress in cancer research, particularly in understanding the molecular and viral mechanisms underlying KS, is leading to the development of more targeted and effective treatments. The growing interest in immunotherapy and targeted therapies is also contributing to market growth, as these approaches offer new hope for patients with treatment-resistant KS. As research continues and access to advanced treatments improves, the KS treatment market is expected to expand, offering better outcomes for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Kaposi Sarcoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (HAART, Chemotherapy, Immunotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 14 Featured) -

• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Kaposi Sarcoma - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Antiretroviral Therapy Expand Treatment Options for Kaposi Sarcoma
  • Increasing Prevalence of HIV/AIDS Propels Demand for Kaposi Sarcoma Therapies
  • Immunotherapy Innovations Strengthen the Business Case for New Treatment Approaches
  • Growing Awareness and Early Detection of Kaposi Sarcoma Throws the Spotlight on Diagnostic Tools
  • Expansion of Cancer Research Funding Accelerates Drug Development for Kaposi Sarcoma
  • Regulatory Approvals for Targeted Therapies Drive Market Growth
  • Shift Towards Combination Therapies Enhances Treatment Efficacy
  • Emerging Markets Present New Opportunities for Kaposi Sarcoma Treatment Providers
  • Clinical Trials and Research Partnerships Propel Innovation in Kaposi Sarcoma Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Kaposi Sarcoma Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Kaposi Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for HAART by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for HAART by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for HAART by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: USA 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: Canada 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• JAPAN
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: Japan 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• CHINA
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: China 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• EUROPE
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Kaposi Sarcoma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Kaposi Sarcoma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: Europe 15-Year Perspective for Kaposi Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: Europe 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• FRANCE
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: France 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• GERMANY
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: Germany 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: Italy 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: UK 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: Rest of Europe 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Kaposi Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: Asia-Pacific 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Kaposi Sarcoma by Treatment Type - HAART, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: Rest of World 15-Year Perspective for Kaposi Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for HAART, Chemotherapy and Immunotherapy for the Years 2015, 2025 & 2030

IV. COMPETITION